PEG-Lipid LNP Formulations for Stable mRNA Storage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The instability and rapid degradation of mRNA formulations in lipid nanoparticles (LNPs) due to lipid degradation and poor stability, especially when stored as refrigerated liquids, hinder effective in vivo delivery and efficacy of mRNA pharmaceutical agents.
Innovation Solution
A method of producing lipid nanoparticles (LNPs) with improved biophysical properties and stability by incorporating specific concentrations of PEG-lipids during different stages of the manufacturing process, including the nanoprecipitation step and excipient addition, to enhance long-term stability and preserve mRNA functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA is encapsulated within conventional lipid nanoparticles, then delivery capability is improved, but stability and purity are rapidly lost during refrigerated storage
Solution Approach 1:
The patent modifies the chemical composition parameters of the lipid nanoparticle by incorporating specific ratios of PEG-lipids (0.25-2.5 mol%), ionizable lipids, phospholipids, and structural lipids. This parameter optimization resolves the contradiction by achieving both improved delivery capability through enhanced cellular uptake and improved stability through reduced lipid degradation and aggregation during refrigerated storage
Solution Approach 2:
The patent creates a composite lipid nanoparticle formulation combining multiple lipid types with specific functional properties. The composite structure includes PEG-lipids for steric stabilization, ionizable lipids for endosomal escape, phospholipids for membrane fusion, and structural lipids for particle integrity. This composite approach simultaneously achieves effective delivery and long-term stability
2Stability of the object's composition
If PEG-lipid concentration is increased to improve stability, then long-term storage stability is enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent incorporates PEG-lipids during the nanoprecipitation step itself, performing the stabilization action preliminarily during formulation rather than requiring separate post-processing steps. This preliminary incorporation of 0.25-2.5 mol% PEG-lipid during manufacturing achieves long-term stability without adding significant process complexity
Solution Approach 2:
The patent optimizes the PEG-lipid concentration parameter to a specific range (0.25-2.5 mol%) that achieves adequate stability without excessive complexity. This parameter optimization balances formulation effectiveness with manufacturing feasibility
Data Source
AI summary
Stabilized formulations of lipids and nucleic acids, including lipid nanoparticle formulations which encapsulate nucleic acids are disclosed herein. Methods of using the formulations are also provided.